Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exosome Inhalation for COVID-19 Pneumonia
NCT04602442Phase 2Unknown
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mesenchymal stem cell exosomes in COVID-19 pneumonia (3 arms). Primary endpoints: Number of participants with non-serious and serious adverse events at 2 months and Number of participants with non-serious and serious adverse events during inhalation procedure at 10 days. Status: unknown.
02
Drugs
mesenchymal stem cell exosomes
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04602442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602442.